My Companies
Notification
Account
Log Out
Login
Coris: FY27 sales +10–15%, slight positive EBITDA; AMR +15–20%; EUR1.41m HAT order due December 2026; IVDR certified; US FDA target 1–2 years
No events have occurred recently